ÂÜÀòÂÒÂ×

Dominique Bridon is currently serving as the CSO and Board Member at Evexta Bio, a clinical stage biopharmaceutical company in Paris focused on developing precision therapies for incurable cancers. Bridon also holds the position of Executive Chairman of the BOD at Sibylla Biotech, which specializes in small-molecule degraders. With experience in various companies such as DPB Bioscience, Concarlo Therapeutics, and EpiVax Oncology, Bridon has a diverse background in peptide technologies and precision cancer immunotherapy. Bridon's educational background includes a Postdoctoral scholar degree in Medicinal chemistry from the University of California, Berkeley and a Master of Science in Chemical Engineering from ENSCCF.